Cortical neuron atrophy is a hallmark of depression and includes neurite retraction, dendritic spine loss, and decreased synaptic density. Psychoplastogens, small molecules capable of rapidly promoting cortical neuron growth, have been hypothesized to produce long-lasting positive effects on behavior by rectifying these deleterious structural and functional changes. Here we demonstrate that ketamine and LSD, psychoplastogens from two structurally distinct chemical classes, promote sustained growth of cortical neurons after only short periods of stimulation. Furthermore, we show that psychoplastogen-induced cortical neuron growth can be divided into two distinct epochs: an initial stimulation phase requiring TrkB activation and a growth peri...
International audienceAbstract Elevated states of brain plasticity typical for critical periods of e...
Background: The neurovascular plasticity of hippocampus is an important theory underlying major dep...
Major depressive disorder (MDD) affects more than 264 million people worldwide. A wide range of anti...
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depress...
Summary: Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology o...
Neural plasticity-the ability to change and adapt in response to stimuli-is an essential aspect of h...
Neural plasticity—the ability to change and adapt in response to stimuli—is an essential aspect of h...
The prevalence of major depressive disorder is increasing despite the increased standard of living. ...
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression a...
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psiloc...
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression a...
In addition to producing profound subjective effects following acute administration, psychedelic com...
In recent years, psychedelics have shown promise in the treatment of conditions like depression and ...
Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resemblin...
In major depression, remission rate in response to monoaminergic antidepressant is around 50%. The ...
International audienceAbstract Elevated states of brain plasticity typical for critical periods of e...
Background: The neurovascular plasticity of hippocampus is an important theory underlying major dep...
Major depressive disorder (MDD) affects more than 264 million people worldwide. A wide range of anti...
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depress...
Summary: Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology o...
Neural plasticity-the ability to change and adapt in response to stimuli-is an essential aspect of h...
Neural plasticity—the ability to change and adapt in response to stimuli—is an essential aspect of h...
The prevalence of major depressive disorder is increasing despite the increased standard of living. ...
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression a...
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psiloc...
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression a...
In addition to producing profound subjective effects following acute administration, psychedelic com...
In recent years, psychedelics have shown promise in the treatment of conditions like depression and ...
Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resemblin...
In major depression, remission rate in response to monoaminergic antidepressant is around 50%. The ...
International audienceAbstract Elevated states of brain plasticity typical for critical periods of e...
Background: The neurovascular plasticity of hippocampus is an important theory underlying major dep...
Major depressive disorder (MDD) affects more than 264 million people worldwide. A wide range of anti...